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Introduction {#sec005}
============

Shock is defined as a state of oxygen delivery that is inadequate to meet vital organ metabolic demands. \[[@pone.0223604.ref001]\] Uncorrected hypoperfusion of vital organs leads to cell injury, multiple organ dysfunction syndrome, and death \[[@pone.0223604.ref002]\]. More specifically, septic (endotoxin-mediated) shock is characterized by an initial peripheral vascular vasodilation with compensatory systemic vasoconstriction as a result of endogenous cardiovascular hormone release in response to hypotension. While preferential regional microcirculatory blood flow (RBF) to preserve vital organ perfusion is essential for survival, maintaining global perfusion is also important for avoidance of long term morbidity and complications of multi-system organ failure. Understanding the effects of shock on whole body and RBF, oxygen consumption, and oxygen delivery are key to guiding resuscitation efforts and improving outcomes. Thus, the therapeutic goal for endotoxic (ET) shock is to achieve hemodynamic stability and to restore microcirculatory flow to all organs \[[@pone.0223604.ref003]--[@pone.0223604.ref005]\].

Extracorporeal Membrane Oxygenation (ECMO) has been used in patients with pulmonary hypertension, respiratory failure, sepsis, and cardiac failure. In children with refractory septic shock, ECMO has been able to successfully support circulation until antibiotics and additional therapies are effective \[[@pone.0223604.ref006]--[@pone.0223604.ref009]\]. While ECMO has been used in patients with sepsis, its effect on regional microcirculatory blood flow distribution has not fully been characterized. In one study of healthy animals, no difference in regional microcirculatory blood flow was noted on ECMO \[[@pone.0223604.ref010]\], but it is unclear whether ECMO maintains adequate distribution of RBF to essential organs in a physiologically stressed state. Further, it is unclear whether matching ECMO flow to restore appropriate MAP during shock is the most appropriate goal. Recent adult studies have questioned the emphasis on blood pressure restoration and vasopressor use in hemorrhagic shock versus a permissive hypotension approach \[[@pone.0223604.ref001],[@pone.0223604.ref011]--[@pone.0223604.ref013]\] and similar alarms regarding its effects in septic shock and children \[[@pone.0223604.ref014]--[@pone.0223604.ref016]\].

In this current study, we used an ET shock model to determine if concurrent vasopressor use with ECMO provides necessary circulatory support to maintain oxygen delivery and redistribution of blood flow to vital organs.

Materials and methods {#sec006}
=====================

This study was approved by the Institutional Animal Care and Use Committee at Tripler Army Medical Center. Investigators complied with the policies as prescribed in the National Research Council's "Guide for the Care and Use of Laboratory Animals" and the USDA Animal Welfare Act. Animals were handled in accordance with the National Institute of Health (NIH) guidelines in facilities fully accredited by the American Association for Accreditation of Laboratory Animal Care International.

Animal preparation {#sec007}
------------------

Yorkshire cross piglets (Oshiro Farms, Waianae, HI) weighing 7--9 kg were sedated before the induction of anesthesia with the following regimens: acepromazine 1.1 mg/kg IM plus Ketamine 22--33 mg/kg IM plus atropine 0.02--0.25 mg/kg IM or with a sedation dose of pentobarbital 30--50 mg/kg intraperitoneal. Anesthesia was maintained with pentobarbital as the anesthetic agent and pigs never regained consciousness throughout the experiment. Pigs were mechanically ventilated to maintain constant tidal volume and end-tidal CO~2~. To assess physiologic measurements, the following catheters were inserted: a 5--6 Fr Swan Ganz catheter with thermistor positioned in the abdominal aorta via left femoral artery access for arterial blood sampling and blood pressure monitoring. A 5--6 Fr Swan Ganz catheter was positioned in the pulmonary artery via left femoral vein access for monitoring of pulmonary pressure, pulmonary artery wedge pressure, and central venous blood sampling. Hemodynamic measurements were recorded continuously throughout the experiment. Cardiac output (CO) was measured via thermodilution of cold 5% dextrose solution injection into Swan Ganz proximal port in right atrium and temperature change measured by a thermistor in main pulmonary artery. When on ECMO, cold bolus was delivered into the left ventricle and temperature change was measured by thermistor in abdominal aorta; the CO measurements thus reflect the total CO of the contributions of both the native heart output flow and ECMO flow. A left ventricle catheter (3.5 Fr) was placed via left internal carotid artery for left ventricular pressure monitoring and injection of colored microspheres for regional blood flow determination. Blood samples were obtained for blood gases and co-oximetry to determine oxygen utilization. Placement of all catheters was verified by observance of characteristic pressure wave forms. A constant infusion of normal saline at 0.1 ml/kg/min i.v. was maintained throughout the experiment to maintain hydration. A Foley catheter was sutured in the bladder through a lower midline mini-laparotomy to monitor urine output throughout the experiment.

Extracorporeal circuit {#sec008}
----------------------

ECMO cannulae were placed for veno-arterial (VA) ECMO in the ET-ECMO groups with a 12--14 Fr cannula aligned with the right atrium via right external jugular vein access, 8--10 Fr cephalad cannula via right external jugular vein (to provide additional venous return), and 8--10 Fr arterial cannula placed at the aortic arch via left carotid artery. ECMO circuits were primed via CO~2~ introduction, 0.9% saline solution, and filled with whole blood harvested within 24hrs from donor pigs (Oshiro Farms, Waianae, HI). Heparin, sodium bicarbonate, and calcium chloride (at one hundred units each) were added to the circuit. The total circuit priming volume was 450 ml. ECMO flow was achieved via centrifugal pump (Jostra-Rotaflow HL20, Maquet, Rastatt, Germany) through a hollow fiber membrane oxygenator (Quadrox, Josta, Maquet, Rastatt, Germany). All piglets received an initial heparin bolus about 75--100 units/kg before cannulation. Activated clotting time (ACT) samples were drawn periodically and additional heparin boluses were given to maintain ACT between 150 and 200 seconds. Once on ECMO, flow was gradually increased to maintain a target 80-100ml/kg/min goal with oxygenation set at 21% FiO~2~ and sweep gas rates (300--400 ml/min) adjusted to maintain pCO~2~ at 35--45 mmHg. Conventional ventilatory support was adjusted for lung rest strategy (respiratory rate halved, baseline positive end expiratory pressure increased, inspiratory time increased, 21% FiO~2~).

Experimental protocol {#sec009}
---------------------

After catheters were placed, a 60 to 120 minute baseline period was allowed ([Fig 1](#pone.0223604.g001){ref-type="fig"}). After baseline measurements were obtained, piglets were randomized to one of 4 groups. The Control group (n = 6), of animals were prepared with all ECMO catheter placements, but not put on ECMO, and monitored continuously for the duration of the experiment with additional measurements obtained at 90 minutes and 3 hours after baseline. Group 2 received ET with no treatment (n = 7), group 3 received ET with ECMO (n = 6), and group 4 received ET with ECMO plus vasopressor treatment (n = 8). For groups 2, 3, and 4, ET shock was induced in piglets with i.v. boluses of *E*. *coli* endotoxin (lipopolysaccharide purified from Escherichia coli serotype 055:B55, cat. No L-2637, 5,000 to 35,000 units, Sigma, St Louis, MO) in 5,000 U increments until a steady state of hypotension was achieved, defined as a minimum 30% decrease in MAP. Initial endotoxin shock state measurements were obtained at 1 hour of hypotension. Repeat measurements for animals in group 2 were obtained after 3 additional hours of hypotension. Group 3 animals were placed on VA ECMO after the initial 1 hour hypotensive period and measurements were obtained after animals had been on ECMO for 3 hours. Animals in group 4 were placed on VA ECMO after the initial 1 hour period of hypotension. After 1 hour on VA ECMO, they received a combination pressor treatment of dopamine (dose titrated 0.006--0.125 mg/kg/min) and vasopressin (dose constant at 30 ng/kg/min) infusions for 2 hours to achieve the goal of returning MAP back to baseline levels.

![Protocol timeline.](pone.0223604.g001){#pone.0223604.g001}

Assessment of Regional Microcirculatory Blood Flow (RBF) {#sec010}
--------------------------------------------------------

During each sampling period, RBF was assessed via injection of colored microspheres (2 x 10^6^ microspheres) over 20 seconds into the left ventricular catheter, followed by saline flush over 10 seconds. Blood was collected at 2ml/min over 70 seconds through the left femoral artery beginning 10 seconds before microsphere injection for assessment of cardiac output at the time of microsphere injection and calculation of RBF based on microsphere concentration (ml/min per gram of tissue). A different colored microsphere was used for each measurement period to distinguish RBF at different periods.

All animals were euthanized with Beuthanasia-D (phenytoin/pentobarbital) and tissues harvested for microsphere extraction. Tissue samples were obtained from skin, muscle, cerebrum, cerebellum, midbrain, brainstem, kidney, heart, liver, small intestine, large intestine, and stomach.

Statistical analyses {#sec011}
--------------------

Two-way Analysis of variance (ANOVA) with repeated measures over time was used to compare hemodynamic measurements, RBF, and oxygen utilization values at the three measurement periods (baseline, after established endotoxin-induced shock, and following treatment within groups) between and within groups (JMP 4.0.4 program, SAS Institute, Cary, NC). Group by period interaction effects that were significant in the overall ANOVA were compared with post hoc orthogonal contrast tests to discern differences between baseline versus ET shock state and ET shock state versus each treatment. Data are expressed as mean ± standard error of the mean. A p value of \<0.05 was considered to be significant.

Results and discussion {#sec012}
----------------------

### Hemodynamics {#sec013}

All control group hemodynamic parameters remained constant at all time points. [Table 1](#pone.0223604.t001){ref-type="table"} Endotoxin caused a dramatic decrease in MAP from baseline due to a drop in CO without a compensatory increase in systemic vascular resistance (SVR) sufficient to prevent hypotension. ECMO support alone, delivered to achieve baseline CO, did not return MAP to baseline. The MAP of untreated ET (group 2) and ET-ECMO (group 3) remained decreased at 61±5 and 63±9 mmHg, respectively. Treatment with vasopressin and dopamine in addition to ECMO (group 4) increased SVR above baseline levels. Vasoconstriction was not changed with ECMO alone, but vasopressors helped increase perfusion pressure with increased SVR. In group 4, vasopressor support returned MAP to baseline levels. ET caused CO to decrease in groups 2, 3, and 4 (236 ± 10 to 145 ± 9ml/kg/min (p\<0.05)). ECMO helped improve CO in group 3. A compensatory increase in HR in response to shock occurred with ET, but with improved CO on ECMO, the tachycardia resolved and returned to baseline.

10.1371/journal.pone.0223604.t001

###### Hemodynamics.

![](pone.0223604.t001){#pone.0223604.t001g}

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                         Control     ET                                                ET+ECMO                                                                              ET+ECMO+Pressors                                                                                                           
  ---------------------- ----------- ------------------------------------------------- ------------------------------------------------------------------------------------ -------------------------------------------------------------------------------------------------------------------------- --
  **MAP**\               Baseline    95±3                                                                                                                                   90±2                                                                                                                       
  **(mm Hg)**                                                                                                                                                                                                                                                                                          

  Endotoxin              93±4                                                          55±2[^a^](#t001fn002){ref-type="table-fn"}                                                                                                                                                                      

  Treatment              89±3        61±5[^a^](#t001fn002){ref-type="table-fn"}        63±9[^a^](#t001fn002){ref-type="table-fn"}                                           100±5[^b^](#t001fn003){ref-type="table-fn"}[^c^](#t001fn004){ref-type="table-fn"}                                          

  **CO**\                Baseline    193±17                                                                                                                                 236±10                                                                                                                     
  **(ml/min/kg)**                                                                                                                                                                                                                                                                                      

  Endotoxin              178±17                                                        145±9[^a^](#t001fn002){ref-type="table-fn"}                                                                                                                                                                     

  Treatment              171±12      132±17[^a^](#t001fn002){ref-type="table-fn"}      178±21[^a^](#t001fn002){ref-type="table-fn"}[^b^](#t001fn003){ref-type="table-fn"}   118±8[^a^](#t001fn002){ref-type="table-fn"}[^b^](#t001fn003){ref-type="table-fn"}[^c^](#t001fn004){ref-type="table-fn"}    

  **SVR**\               Baseline    459±21                                                                                                                                 387±20                                                                                                                     
  **(mmHg/(L/min/kg)**                                                                                                                                                                                                                                                                                 

  Endotoxin              532±44                                                        387±32                                                                                                                                                                                                          

  Treatment              522±39      447±32                                            329±25                                                                               814±48[^a^](#t001fn002){ref-type="table-fn"}[^b^](#t001fn003){ref-type="table-fn"}[^c^](#t001fn004){ref-type="table-fn"}   

  **SV**\                Baseline    1.2±0.1                                                                                                                                1.6±0.1                                                                                                                    
  **(ml/beat)**                                                                                                                                                                                                                                                                                        

  Endotoxin              1.1±0.1                                                       0.7±0.1[^a^](#t001fn002){ref-type="table-fn"}                                                                                                                                                                   

  Treatment              0.9±0.1     0.7±0.2[^a^](#t001fn002){ref-type="table-fn"}     1.2±0.2[^a^](#t001fn002){ref-type="table-fn"}                                        0.8±0.1[^a^](#t001fn002){ref-type="table-fn"}[^b^](#t001fn003){ref-type="table-fn"}                                        

  **HR**\                Baseline    163±13                                                                                                                                 155±5                                                                                                                      
  **(beats/min)**                                                                                                                                                                                                                                                                                      

  Endotoxin              169±13                                                        207±8[^a^](#t001fn002){ref-type="table-fn"}                                                                                                                                                                     

  Treatment              186±8       200±18[^a^](#t001fn002){ref-type="table-fn"}      163±17[^b^](#t001fn003){ref-type="table-fn"}                                         147±12[^b^](#t001fn003){ref-type="table-fn"}                                                                               

  **SvO2**               Baseline    0.71±0.02                                                                                                                              0.78±0.02                                                                                                                  

  Endotoxin              0.71±0.02                                                     0.54±0.03[^a^](#t001fn002){ref-type="table-fn"}                                                                                                                                                                 

  Treatment              0.72±0.01   0.47±0.05[^a^](#t001fn002){ref-type="table-fn"}   0.84±0.03[^b^](#t001fn003){ref-type="table-fn"}                                      0.78±0.04[^b^](#t001fn003){ref-type="table-fn"}                                                                            
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Values represent mean ± s.e.m.

^a^ = significantly different from baseline, p\<0.05.

^b^ = significantly different from ET during endotoxin period 2, p\<0.05.

^c^ = significant difference between ECMO only and ECMO plus vasopressors, p\<0.05

During endotoxic shock, decreased perfusion was associated with decreased mixed venous oxygen saturations, indicative of increased oxygen extraction at the tissue level. ECMO with or without vasopressors increased oxygen delivery, and hence was able to improve SvO2 to pre-shock levels.

ET induced pulmonary hypertension in groups 2, 3, and 4, which persisted in non-ECMO treated animals in group 2. ECMO increased oxygen delivery and thus ameliorated hypoxemia which led to some improvement in pulmonary pressure ([Fig 2A](#pone.0223604.g002){ref-type="fig"}). With improved oxygenation, ECMO decreased PVR to baseline levels in groups 3 and group 4 ([Fig 2B](#pone.0223604.g002){ref-type="fig"}). The PVR/SVR ratio was normalized in group 4 with the addition of vasopressors ([Fig 2C](#pone.0223604.g002){ref-type="fig"}).

![Pulmonary function.\
A. Pulmonary Artery Pressure B. Pulmonary Vascular Resistance C. PVR/SVR ratio. Values represent mean ± s.e.m. \* = significantly different from baseline, p\<0.05. \# = significantly different from ET during endotoxin period 2, p\<0.05. † = significant difference between ECMO only and ECMO plus vasopressors, p\<0.05.](pone.0223604.g002){#pone.0223604.g002}

Oxygen utilization {#sec014}
------------------

ET caused a decrease in overall oxygen delivery ([Fig 3A](#pone.0223604.g003){ref-type="fig"}). This decreased oxygen delivery continued in untreated ET shock animals. In animals placed on ECMO, O2 delivery improved towards baseline and was significantly higher than untreated ET, but did not return to baseline due to persistently decreased cardiac output. The addition of vasopressors did not further improve overall oxygen delivery.

![Oxygen utilization.\
A. Oxygen delivery B. Oxygen consumption C. Oxygen extraction. Values represent mean ± s.e.m. \* = significantly different from baseline, p\<0.05. \# = significantly different from ET during endotoxin period 2, p\<0.05. † = significant difference between ECMO only and ECMO plus vasopressors, p\<0.05.](pone.0223604.g003){#pone.0223604.g003}

Despite the differences in decreased delivery, oxygen consumption was sustained in ET animals through increased oxygen extraction ([Fig 3B and 3C](#pone.0223604.g003){ref-type="fig"}). When animals were placed on ECMO, oxygen consumption and extraction were decreased from the ET period, likely due to the restoration of blood flow with VA ECMO. Vasopressin and dopamine pressor treatment did not alter the effect of ECMO on oxygen consumption and extraction. As ECMO improved systemic circulation and decreased tachycardia, the decreased oxygen consumption is consistent with a reduced cardiac work with ECMO.

Regional microcirculatory blood flow {#sec015}
------------------------------------

For the various organs examined, RBF remained unchanged at all time periods in the control group. [Table 2](#pone.0223604.t002){ref-type="table"} RBF to all areas of the brain was maintained in all groups, showing preservation of cerebral blood flow in early septic shock. Blood flow to different regions of the brain (brainstem, midbrain) increased slightly in the endotoxin groups.

10.1371/journal.pone.0223604.t002

###### Regional microcirculatory blood flow.

![](pone.0223604.t002){#pone.0223604.t002g}

                                     Control                                           ET                                                ET+ECMO                                           ET+ECMO+Pressors                                                                                                              
  ---------------------------------- ------------------------------------------------- ------------------------------------------------- ------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------- --
  **Cerebrum RBF (ml/min/kg)**       Baseline                                          0.51±0.12                                                                                           0.50±0.04                                                                                                                     
  Endotoxin                          0.57±0.17                                                                                           0.52±0.06                                                                                                                                                                       
  Treatment                          0.56±0.07                                         0.53±0.15                                         0.53±0.08                                         0.54±0.08                                                                                                                     
  **Cerebellum RBF (ml/min/kg)**     Baseline                                          0.57±0.10                                                                                           0.67±0.04                                                                                                                     
  Endotoxin                          0.67±0.16                                                                                           0.80±0.09                                                                                                                                                                       
  Treatment                          0.69±0.06                                         0.73±0.18                                         0.70±0.11                                         0.99±0.16[^a^](#t002fn002){ref-type="table-fn"}                                                                               
  **Midbrain RBF (ml/min/kg)**       Baseline                                          0.36±0.05                                                                                           0.47±0.03                                                                                                                     
  Endotoxin                          0.41±0.07                                                                                           0.57±0.05[^a^](#t002fn002){ref-type="table-fn"}                                                                                                                                 
  Treatment                          0.44±0.05                                         0.50±0.12                                         0.45±0.06                                         0.65±0.08[^a^](#t002fn002){ref-type="table-fn"}                                                                               
  **Brainstem RBF (ml/min/kg)**      Baseline                                          0.36±0.06                                                                                           0.51±0.03                                                                                                                     
  Endotoxin                          0.42±0.08                                                                                           0.70±0.09[^a^](#t002fn002){ref-type="table-fn"}                                                                                                                                 
  Treatment                          0.49±0.07                                         0.62±0.16                                         0.48±0.08                                         0.70±0.10                                                                                                                     
  **Heart RBF (ml/min/kg)**          Baseline                                          1.71±0.28                                                                                           1.67±0.12                                                                                                                     
  Endotoxin                          1.69±0.38                                                                                           2.01±0.20                                                                                                                                                                       
  Treatment                          1.59±0.22                                         2.31±0.43                                         1.28±0.23[^b^](#t002fn003){ref-type="table-fn"}   1.17±0.14[^b^](#t002fn003){ref-type="table-fn"}                                                                               
  **Kidney RBF (ml/min/kg)**         Baseline                                          3.00±0.42                                                                                           2.80±0.14                                                                                                                     
  Endotoxin                          2.93±0.36                                                                                           1.74±0.20[^a^](#t002fn002){ref-type="table-fn"}                                                                                                                                 
  Treatment                          2.74±0.25                                         1.78±0.32                                         3.00±0.74[^b^](#t002fn003){ref-type="table-fn"}   2.57±0.65                                                                                                                     
  **Liver RBF (ml/min/kg)**          Baseline                                          0.93±0.22                                                                                           0.96±0.08                                                                                                                     
  Endotoxin                          0.78±0.21                                                                                           0.33±0.06[^a^](#t002fn002){ref-type="table-fn"}                                                                                                                                 
  Treatment                          0.51±0.11[^a^](#t002fn002){ref-type="table-fn"}   0.28±0.07[^a^](#t002fn002){ref-type="table-fn"}   0.21±0.05[^a^](#t002fn002){ref-type="table-fn"}   0.64±0.12[^a^](#t002fn002){ref-type="table-fn"}[^b^](#t002fn003){ref-type="table-fn"}[^c^](#t002fn004){ref-type="table-fn"}   
  **Stomach RBF (ml/min/kg)**        Baseline                                          0.23±0.04                                                                                           0.36±0.03                                                                                                                     
  Endotoxin                          0.26±0.08                                                                                           0.32±0.03                                                                                                                                                                       
  Treatment                          0.26±0.04                                         0.37±0.11                                         0.41±0.09                                         0.19±0.02[^a^](#t002fn002){ref-type="table-fn"}[^c^](#t002fn004){ref-type="table-fn"}                                         
  **Sm Intestine RBF (ml/min/kg)**   Baseline                                          0.78±0.15                                                                                           0.99±0.11                                                                                                                     
  Endotoxin                          0.91±0.33                                                                                           0.68±0.07[^a^](#t002fn002){ref-type="table-fn"}                                                                                                                                 
  Treatment                          0.80±0.13                                         0.73±0.21                                         1.12±0.25[^b^](#t002fn003){ref-type="table-fn"}   0.66±0.06                                                                                                                     
  **Lg Intestine RBF (ml/min/kg)**   Baseline                                          0.62±0.08                                                                                           0.76±0.07                                                                                                                     
  Endotoxin                          0.64±0.12                                                                                           0.51±0.06[^a^](#t002fn002){ref-type="table-fn"}                                                                                                                                 
  Treatment                          0.82±0.18                                         0.51±0.08                                         0.74±0.16                                         0.55±0.11                                                                                                                     

Values represent mean ± s.e.m.

^a^ = significantly different from baseline, p\<0.05.

^b^ = significantly different from ET during endotoxin period 2, p\<0.05.

^c^ = significant difference between ECMO only and ECMO plus vasopressors, p\<0.05

Blood flow was maintained to the heart with ET despite the decrease in MAP. ECMO with and without pressors decreased heart microperfusion below ET levels, likely due to the partial cardiac bypass of flow to the ECMO circuit.

ET caused a decrease in renal blood flow, commensurate with the overall decrease in perfusion pressure with shock. ECMO helped increase overall perfusion and accordingly, renal blood flow. Vasopressors did not alter this ECMO-induced return of renal blood flow towards baseline.

The overall decrease in MAP with ET was also associated with a 60% decrease in liver blood flow. Liver RBF remained depressed with ECMO whereas ECMO with vasopressors helped return liver blood flow towards baseline.

The ET-induced drop in MAP caused a decrease in blood flow to the small and large intestines but no change in flow to the stomach. ECMO did not affect the flow to the stomach but increased blood flow to the small intestines so that it was no longer depressed from baseline. The addition of vasopressors negated the ECMO effect on the intestines.

Discussion {#sec016}
==========

Decreased perfusion pressure observed during ET shock redistributes blood in the peripheral circulation and decreases venous return that can lead to cardiac failure. Cardiac depression is proportional to the severity of sepsis \[[@pone.0223604.ref017],[@pone.0223604.ref018]\], and cardiovascular support strategies in septic shock need to address prevention of global circulatory dysfunction. Increasing ECMO flow to achieve pre-hypotension baseline MAP may risk over-perfusing certain vascular beds as we demonstrated in a previous study \[[@pone.0223604.ref019]\] which showed that using normotensive MAP as a criteria for setting ECMO flow caused an increase in brain blood flow which could lead to cerebral hemorrhage risk. Conversely, if ECMO flow is not high enough to achieve an adequate perfusion pressure, microcirculatory flow to vital organs may be insufficient.

Mixed venous saturation (SvO2) has been used as a clinical indicator of adequate O2 delivery with a therapeutic goal of SvO2 \> 70% \[[@pone.0223604.ref020]\]. Previous to this study, it has been unclear how reduced overall CO while on ECMO would affect blood flow distribution to various vascular beds. Vasopressor therapy is commonly used to achieve normotensive MAP, yet it is unclear how the pressor-induced vasoconstriction may, in itself, reduce flow to certain vascular beds.

In this study we demonstrated that VA ECMO is able to achieve adequate blood flow, and thereby adequate oxygen delivery even when neither MAP nor CO returned to baseline. Persistent pulmonary hypertension contributes to worsening hypoxemia in endotoxic shock. We previously showed that vasopressin spares the pulmonary vasculature of its potent vasoconstrictive action \[[@pone.0223604.ref021]\], thus it was not surprising to see that when vasopressin and dopamine were used in conjunction with ECMO that the elevated pulmonary to systemic vascular resistance ratio (PVR/SVR) caused by ET returned to baseline. Because oxygen delivery was already increased with ECMO alone, the relative vasoconstrictive sparing of the pulmonary bed did not contribute additional systemic oxygen delivery gains.

There did not seem to be any immediate adverse systemic vasoconstrictive effect seen with the use of vasopressors. In striving for restoration of pre-illness MAP and CO, there may not be a clear benefit to overall total systemic oxygen utilization, however the benefit of using vasopressors may be the redistribution of microcirculatory flow to vital organs. These findings could support recent discussions about permissive hypotension to simply achieve minimal perfusion pressure, and the benefit of vasopressor use in septic shock \[[@pone.0223604.ref012],[@pone.0223604.ref014],[@pone.0223604.ref016]\].

Our study presents a comprehensive picture of RBF in all major organ systems during early ET shock in an ECMO model incorporating vasopressor use. Earlier studies implicated preferential blood flow toward the upper body with ECMO delivery compared with left ventricular outflow supplying blood to the heart and lower body \[[@pone.0223604.ref022]\]. During early ET shock when endogenous vasopressin is elevated, regional microcirculatory blood flow is directed to certain organs such as the brain and heart, which supports previously reported findings that vasopressin redistributes microcirculatory flow to vital organs and increases brain blood flow in hypotensive shock via selective vasoconstriction of vascular beds \[[@pone.0223604.ref023]\]. The vasoconstrictive effects of vasopressin and dopamine remained evident even during ECMO. Thus vasopressor agents may be beneficial not only for restoring blood pressure, but also for re-distributing microcirculatory blood flow to maintain vital organ tissue viability in septic shock.

We note with interest that ET increased RBF to midbrain and brainstem but that ECMO normalized it. Vasopressors with ECMO increased brain RBF possibly via redistribution from the intestines. Cardiac RBF was maintained with ET and as might be expected, decreased with partial cardiac bypass on ECMO, and vasopressors did not further alter heart microcirculatory flow. ET also caused a decrease in renal RBF in accordance with decreased perfusion pressure during hypotension. Smith et al reported distribution of RBF toward the brain and away from heart and kidneys in a lamb model on ECMO and found no significant differences in the spleen, lung, or liver \[[@pone.0223604.ref024]\]. However, our data report that ECMO both alone and with vasopressors returned renal RBF to baseline levels. Blood flow to intestinal organs (stomach, SI, LI) was unchanged or improved in the ECMO only group, but this effect was negated with the addition of vasopressors. The ET-induced decrease in liver blood flow persisted with ECMO but improved with the addition of vasopressors. This effect is likely due to vasopressin which is known to increase liver blood flow \[[@pone.0223604.ref023]\].

There are limitations to our study. Prolonged hypotension and alterations in microcirculation in sepsis occur over several days, and ECMO therapy and vasopressor requirements can persist for days to weeks. Therefore, our short experimental timeline does not permit interpretation of ECMO (with and without vasopressors) effects beyond the initial period in ET shock. Vasopressin and dopamine were chosen for this protocol based upon investigators' experience with these vasopressors both in clinical and experimental settings. We acknowledge that many other vasopressors are used to manage septic shock, and our findings limit the ability to extrapolate to other commonly used vasopressors, such as norepinephrine or dobutamine. Lastly, we also acknowledge the inherent limitations of using non-human species in translational research.

Conclusions {#sec017}
===========

In conclusion, extracorporeal support and concurrent vasopressor use sustained and improved regional blood flow and oxygen delivery in this model of early ET shock even in the absence of fully restoring MAP or CO to baseline. Additionally, ECMO and concurrent vasopressors re-distribute RBF preferentially to vital organ systems. Results suggest that the therapeutic goal in using ECMO should be to maximize blood flow and oxygen delivery to vital organs rather than simply trying to restore blood pressure *per se*. Further studies, particularly incorporating longer ECMO periods and different vasopressors are needed to fully characterize the effects of ECMO therapy on microcirculatory flow and oxygen utilization in septic shock.

We would like to acknowledge Wayne Ichimura, Aileen Sato, and Claudia Hernandez for all of the support they provided with helping the experimental protocol run smoothly.
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We would appreciate receiving your revised manuscript by Sep 15 2019 11:59PM. When you are ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter.

To enhance the reproducibility of your results, we recommend that if applicable you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). This letter should be uploaded as separate file and labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. This file should be uploaded as separate file and labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. This file should be uploaded as separate file and labeled \'Manuscript\'.

Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

We look forward to receiving your revised manuscript.

Kind regards,

Michael Bader

Academic Editor

PLOS ONE

Journal Requirements:

1\. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at

<http://www.journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf> and <http://www.journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

2\. At this time, we request that you  please report additional details in your Methods section regarding animal care:

\*The method of euthanasia

\*The source of the pigs and the source of the donor pig blood used in this study.

\* Please clarify whether the pigs were anesthetized throughout the experiments, or whether the ever regained consciousness.

. Thank you for your attention to these requests.
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Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#2: Partly

\*\*\*\*\*\*\*\*\*\*

2\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#2: I Don\'t Know

\*\*\*\*\*\*\*\*\*\*

3\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Findings are consistent with previous clinical and research studies. A group with shock and vasopressors without echo would have been interesting.

Reviewer \#2: Dear authors

It has been a pleasure to write and comment on your article: "ECMO with vasopressor..."

As you can see below, I have something that need changes and I have some suggestions for improvement.

Introduction:

The section is well written and appropriate.

Line 46: MODS as an abbreviation is not necessary because it is not used again in the text.

Materials and Methods:

Even though the local authorities approved the study, the anesthesia was not in accordance with European standard. In Europe, a protocol with Pentobarbital without analgesics cannot be accepted in surgery. Was the anesthesia as described or is anything missing?

How was the ventilator settings during the experiments? FiO2 and how was the ventilator and oxygenator air flow adjusted?

Extracorporeal Circuit:

Please explain why a cephalad 8-10 Fr catheter was inserted in the jugular vein, line 107

On line 108: arterial cannula placed at the left ventricle? Is it in the aortic arch or in the descending aorta at the level of the left ventricle? If placed in the ventricle it may result in valve insufficiency and backward failure to the pulmonary circulation. In line 96 another catheter is placed via the same internal carotid artery and inserted to the left ventricle. I guess this is a smaller catheter, please mention.

A priming volume 450 ml is very big for a 9 kg pig even the circuit was primed with blood. The donor blood can interfere with pulmonary resistance. Did the control group that was not on ECMO receive donor blood?

Why not use an infant set for ECMO, or bigger pigs, instead of using a 50 kg pig as donor.

I think the extra corporeal system was biocoated, if it was possible to run the ECMO with an ACT below 200 seconds.

Experimental protocol:

The first group, if I understand it correct, please indicate that the pigs were prepared for ECMO with all catheters inserted but the ECMO was not started.

Line 125: n=21. Please mention how many in each group first and then about ET treatment.

Why did you end at 27 pigs? How many pigs did you have from the beginning?

Results:

Line 190: be careful not to conclude something of PAP, but only about PVR, because ECMO in itself will bypass blood from the pulmonary circulation.

Line 2019: Maybe better to change CO with systemic circulation

Discussion:

Line 255 to 270 is strictly not discussion but introduction

The biggest limitation is the species difference.

Very best

Benedict Kjaergaard

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Benedict Kjaergaard

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.
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Dear Dr. Mu,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.

With kind regards,

Michael Bader

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#2: All comments have been addressed

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: (No Response)

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: Revisions complete. Comments worthwhile and appropriately placed in manuscript. Nothing further to add to this review.

Reviewer \#2: I find the changes acceptable for publication. Especially that you changed the sections of medication, cannulas and ventilator settings. Your explanation of the statistics is OK.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: Yes: Irving Kron

Reviewer \#2: Yes: Benedict Kjaergaard
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Dear Dr. Mu:

I am pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please notify them about your upcoming paper at this point, to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact <onepress@plos.org>.

For any other questions or concerns, please email <plosone@plos.org>.

Thank you for submitting your work to PLOS ONE.

With kind regards,

PLOS ONE Editorial Office Staff
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Prof. Michael Bader

Academic Editor
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